NCT03823144Recruiting
Intravital Microscopy in Human Solid Tumors
Intravital Microscopy (IVM) in Human Solid Tumors
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- First submitted
- 28 Jan 2019
- Start date
- 28 Feb 2019
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Pancreatic cancer, Metastatic breast cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Sarcoma
- NCT number
- NCT03823144
What you commit to
- Study type: Interventional
- Planned participants: 85
- From 28 Feb 2019 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein
Other illness
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
- Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography \[EKG\], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test)
- Any condition that excludes surgical resection as the standard of care for the patient
Lab values
- Renal dysfunction as defined as a glomerular filtration rate (GFR) \< 45
Other
- Liver dysfunction as defined by Child-Pugh score \> 5, or liver function test (LFT)'s 1.5 x above normal range
- Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test
- Unwilling or unable to follow protocol requirements
Who the study is looking for
- Age ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2
- Measurable tumor by direct visualization requiring surgical resection in the operating room (OR)
- Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic
- Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent
- Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.